Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-079-6 | CAS number: 102242-48-8 The complex residue resulting from the vacuum distillation of C6-24 and C6-24 unsatd. fatty alcohols which is derived from hydrogenation of C6-24 and C6-24 unsatd. fatty acids methyl esters. It consists predominantly of satd. and unsatd. fatty alcohols having carbon numbers greater than C18, dimerization products, and long chain esters having carbon numbers greater than C32 and boils at > 250°C (482°F) at 10 torr.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A subchronic orientating study (13 weeks, rat, gavage) conducted 1980 according to an in house protocol (Henkel R 9500428, 1980) is available. Since the study was conducted prior to the implementation of currently acknowledged testing guidelines (OECD TG 408), current testing requirements are not fulfilled; nevertheless the study provides suitable basic data, acceptable for assessment of the toxic potential of the compound following repeated dosing.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 250 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Additional information
Exposure based adaptation of information requirements:
According to REGULATION (EC) No 1907/2006, Annex IX and Annex X, repeated dose toxicity testing (section 8.6) may be omitted, if relevant human exposure can be excluded in accordance with Annex XI section 3. Furthermore and in accordance with section 3.2 (b) of Annex XI (as amended by Regulation 134/2009), testing for repeated dose toxicity can be omitted when the substance is not incorporated in an article and the manufacturer can demonstrate and document for all relevant scenarios that throughout the life cycle strictly controlled as well as rigorously contained conditions as set out in Article 18(4)(a) to (f) (Regulation 1907/2006) apply.
Life-cycle stage(s) covered:
1.Production of distillation residues (PROCs 1, 8b)
2.Use of distillation residues in production of energy products (PROC 1, 3, 8b)
3.Use of distillation residues as renewable energy source (PROC 1, 8b, 16)
Classification:
H341: Suspected of causing genetic defects.
The substance is not harmful after single ingestion and single dermal application. Additionally, the substance is not considered to be corrosive to skin as well as the eyes. The substance is not a skin sensitizer. No effects occurred in the bacterial reverse mutation assay and the HPRT assay. Based on effects in the micronucleus test the test substance is considered to be mutagenic in the absence of a metabolic activation system.
Process description:
Saturated and/or unsaturated fatty acids or triglycerides are transferred to methyl esters by esterification/transesterification processes with Methanol. Methylesters are transferred to saturated and unsaturated fatty Alcohols by partial catalytic reduction with hydrogen. The Fatty alcohols are purified by vacuum distillation, delivering fatty alcohols in the distillate and the distillation residues, which are topic of this registration in the distillation sump.
After the destillation is completed, the distillation residue is transferred via a closed dedicated pipeline to a buffer tank, where the residue is stored at 40-50°C. Sampling is not required for this process step. The reactor can immediately be used for the next destillation.
The process is operated discontinuously at elevated temperature. The reactor is located outdoors. Due to the closed system, exposure to workers will not take place under normal operation conditions.
Thereafter, the distillation residue is transported from the storage tank to the filling station under strictly controlled conditions. Here, the residue is filled in a transport vehicle under strictly controlled conditions. Exposure to workers will not take place under normal operation conditions. Then, the residue is transported to the powerplant via street where it is blended with other residues or directly pumped into the powerplant under strictly controlled conditions.
The substance is used as fuel in powerplants in closed systems similar to mineral oil products.The use is dedicated to large powerplants industrial style with the confirmation of strictly controlled conditions similar to the use of on site resprective transported intermediates. Any widespread use by professional workers or consumers (e. g. in neighbourhood small block heat and powerplants) is a use advised against.
Rigorous containment measures:
The substance is manufactured and used under strictly controlled conditions over the entire lifecycle. Transport, storage tanks, reactors and processing equipment operate in fully closed systems.
Procedural and control technologies are used to minimise residual emissions/exposure as well as qualitative risk considerations:
Operational and technical conditions and measures affecting and controlling workers exposure, as well as personal protective equipment, such as goggles, chemically resistant gloves, and respiratory protection where potential exposure may occur as reported in the CSR are followed (see chapters 9 & 10).
On the basis of the described process conditions, testing of the distillation residue in a sub-chronic toxicity study (OECD 408) was not performed since the criteria of exposure based adaptation of information requirements are met.
One study of a read across substance gives indication of no toxicity after repeated exposure. A repeated dose study was conducted using Wistar rats (Henkel R 9500428). The study was conducted prior to the implementation of acknowledged guidelines, and thus, does not fulfill all today's requirements for the testing of oral repeated dose toxicity. One group of 30 male and 30 female Wistar rats was given and oral dose 250 mg/kg bw/d of the test item in 1% CMC, by gavage, once a day, 5 days a week, over 12 -13 weeks. A further group of 30 male and 30 female animals was treated similarly but with the vehicle only, and served for control. An additional control group with 20 male and 20 female animals was added, which was used for blood sampling at test initiation. All animals were examined for mortality, clinical symptoms, body weight and body weight gain, haematological and clinical chemical parameters, and urine parameters. At test ending, all animals were sacrificed for the purpose of necropsy, which included gross pathology, organ weighing and histopathology.
Neither mortalities nor clinical symptoms indicative of toxicity were noticed, and no treatment-related changes in body weight and body weight gain were recorded. Regarding haematology, changes in haematocrit and MCV were reported, which however were not considered to be treatment-related as the measured values were within the range considered as normal for the strain used and the age of the animals. Regarding clinical chemistry, a weak increase in alanine aminotransferase (GPT) and a more significant
increase in aspartate aminotransferase (GOT) were reported for treated females but not for the males. These changes, especially for GOT, were considered to be related to treatment, but were not considered to represent adverse effects, since no corresponding changes in liver weight and/or histology were noticed. Urinalysis, feces excretion, organ weights, gross pathology and histopathology showed no changes/lesions which could be attributed to the treatment.
Thus, based on the results reported above, and since no clear treatment-related effects could be evidenced for the test item at the dose level of 250 mg/kg bw/d, the No-Observed-Adverse-Effect-level (NOAEL) was set at 250 mg/kg bw/day.
Justification for classification or non-classification
Based on the available data, no classification according to the EU Directive 67/548/EEC and the CLP Regulation (EC) No. 1272/2008 is needed for "alcohols, C6-C24 and C6 -C24 unsat., distn residues" (CAS 102242 -48 -8).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.